Effects of Trichromium Picolinate on Histopathological Changes in Testosterone-Induced Polycystic Ovary Syndrome in Female Rats

Israa Ali Abdul Ghani; Nadia H Mohammed; Bahir Abdul Razzaq Mshimesh; Rawia Abdelhadi Elsayed Zayed

doi:10.32947/ajps.v25i4.1203

Authors

Israa Ali Abdul Ghani Mustansiriyah University/College of pharmacy, Department of Pharmacology and Toxicology, Baghdad, Iraq
Nadia H Mohammed Mustansiriyah University/college of medicine, Department of Microbiology and Immunology, Baghdad, Iraq
Bahir Abdul Razzaq Mshimesh Mustansiriyah University/College of pharmacy, Department of Pharmacology and Toxicology, Baghdad, Iraq
Rawia Abdelhadi Elsayed Zayed Zagazig University/College of pharmacy, Department of Pharmacognosy, Cairo, Egypt

DOI:

https://doi.org/10.32947/ajps.v25i4.1203

Keywords:

Polycystic ovary syndrome, Trichromium picolinate, testosterone enanthate, cyproterone acetate

Abstract

Polycystic ovary syndrome (PCOS) is the most prevalent disorder, establishing the single most common endocrine-metabolic disorder in women of reproductive age. Currently there are four recognized phenotypes of PCOS: 1) hyperandrogenism + oligo-anovulation + polycystic ovarian morphology; 2) hyperandrogenism + oligo-anovulation; 3) hyperandrogenism + polycystic ovarian morphology; and 4) oligo-anovulation + polycystic ovarian morphology, each having different long-term effects and metabolic consequences.

The histology of ovarian PCOS patients demonstrates that PCOS ovaries showed multiple ovarian cysts with a lack of corpus luteum, growing follicles, oocytes, granulosa, and theca cell layers. Chromium picolinate Chromium picolinate is a salt of the trace metallic element chromium (Cr). It is effectively treating hyperinsulinemia and hyperlipidemia.

This study aimed to investigate the effects of different doses of trichromium picolinate on the ovary histopathologic changes.

Methods: Forty-eight female albino rats were divided into six groups, with eight animals in each group. All groups were given testosterone enanthate 100 mg/kg/day by subcutaneous injection for 28 days, while the control group was given sesame oil 0.5 ml for 28 days. In the treatment stage, trichromium picolinate (1 mg, 2 mg, and 4 mg/kg/day) was given to groups III, IV, and V, respectively, for 42 days, and cyproterone acetate was given to group VI for comparison. At the same time, control and induction groups were treated with distilled water 0.5 mL orally for 42 days. In the current study, ovary histopathological changes were examined by hematoxylin and eosin staining.

Results: The control group showed apparently normal histology of ovarian rat’s tissue with all types of follicles at different stages of maturation. Furthermore, the oocyte was intact, surrounded by granulosa and visible theca cell layers with numbers of corpus luteum. Conversely, the induction group confirmed PCOS in ovarian rat’s tissue, which exhibited numerous cystic follicles and atretic follicles, granulosa, and theca layer hyperplasia with a decrease in the number of developing follicles and the absence of corpus luteum. Histopathological examination of the treatment groups with different doses of trichromium picolinate demonstrated dose-dependent manner. Treatment with trichromium picolinate (1 mg/kg) mildly improved the histopathological changes of the ovary. When the dose was increased to 2 mg/kg, the score improved additionally, with the ovarian tissue resolving at 4 mg/kg of trichromium picolinate as in the cyproterone acetate group.

Conclusions: Trichromium picolinate can improve histopathological changes in the ovarian tissue of female rats.

References

1- Deans R. Polycystic ovary syndrome in adolescence. Medical Sciences. 2019 Oct 2;7(10):101.

2- Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. Journal of the Endocrine Society. 2019 Aug;3(8):1545-73.

3- Dong J, Rees DA. Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. BMJ medicine. 2023;2(1):000548

4- Shaheed HS, Abbass WAK, Jasim SY. Studying Cytotoxic T-lymphocyte-Associated Antigen-4 (CTLA-4) gene Polymorphism in a Sample of Iraqi Women with Polycystic Ovarian Syndrome. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2019;19(4):1–6.

5- Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clinica chimica acta. 2020 Mar 1; 502:214-21.

6- Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary NS, Gambineri A, Garcia Rudaz C. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Hormone research in paediatrics. 2017 Jun 1;88(6):371-95.

7- Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian Journal of Medical Research. 2019 Oct 1;150(4):333-44.

8- Silva EG, Kim G, Bakkar R, Bozdag Z, Shaye-Brown A, Loghavi S, Stolnicu S, Hadareanu V, Bulgaru D, Cayax LI, Pitalua MC. Histology of the normal ovary in premenopausal patients. Annals of Diagnostic Pathology. 2020 Jun 1; 46:151475.

9- Jonard S, Robert Y, Ardaens Y, Dewailly D. Ovarian histology, morphology, and ultrasonography in the polycystic ovary syndrome. Androgen Excess Disorders in Women: Polycystic Ovary Syndrome and Other Disorders. 2007:183-93.

10- Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes care. 2007 Aug 1;30(8):2154-63.

11- Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta‐analysis of the efficacy and safety of chromium supplementation in diabetes. Journal of clinical pharmacy and therapeutics. 2014 Jun;39(3):292-306.

12- Chen J, Kan M, Ratnasekera P, Deol LK, Thakkar V, Davison KM. Blood chromium levels and their association with cardiovascular diseases, diabetes, and depression: national health and nutrition examination survey (NHANES) 2015–2016. Nutrients. 2022 Jun 28;14(13):2687.

13- Alvarez CC, Gómez ME, Zavala AH. Hexavalent chromium: Regulation and health effects. Journal of trace elements in medicine and biology. 2021 May 1; 65:126729.

14- Plaza SM, ND L. The safety and efficacy of high-dose chromium. Alternative Medicine Review. 2002;7(3):218-35.

15- Emamdoost M, Zafar-Balanejad S, Shahrokhabadi K, Homayouni M. A comparison between antioxidant effects of Korean red ginseng extract (KRGE)-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles and Korean red ginseng extract (KRGE) in the treatment of testosterone-induced polycystic ovarian syndrome.

16- Sundaram B, Aggarwal A, Sandhir R. Chromium picolinate attenuates hyperglycemia-induced oxidative stress in streptozotocin-induced diabetic rats. Journal of Trace Elements in Medicine and Biology. 2013 Apr 1;27(2):117-21.

17- Qi SS, Zheng HX, Jiang H, Yuan LP, Dong LC. Protective effects of chromium picolinate against diabetic-induced renal dysfunction and renal fibrosis in streptozotocin-induced diabetic rats. Biomolecules. 2020 Mar 4;10(3):398.

18- Ruan X, Kubba A, Aguilar A, Mueck AO. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. The European Journal of Contraception & Reproductive Health Care. 2017 May 4;22(3):183-90.

19- Suvarna KS, Layton C, Bancroft JD. Bancroft's theory and practice of histological techniques. Elsevier health sciences; 2018 Feb 27:12-40

20- Alghulami OM, Jasim GA, Jasim SY. Histopathological evaluation of docetaxel effects in treatment of rheumatoid arthritis induced in rat model. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2023;23(2):168–79.

21- Khani S, Abdollahi M, Khalaj A, Heidari H, Zohali S. The effect of hydroalcoholic extract of Nigella Sativa seed on dehydroepiandrosterone-induced polycystic ovarian syndrome in rats: An experimental study. International Journal of Reproductive BioMedicine. 2021 Mar;19(3):271.

22- Sedigheh Amooee MD, Akbarzadeh-Jahromi M, Motavas MD, Zarei F. Comparing endometrial hysteroscopic and histological findings of infertile women with polycystic ovary syndrome and unexplained infertility: A cross-sectional study.

23- Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical epidemiology. 2013 Dec 18:1-3.

24- Banaszewska B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. American journal of obstetrics and gynecology. 2006 May 1;194(5):1266-72.

25- Duleba AJ. Medical management of metabolic dysfunction in PCOS. Steroids. 2012 Mar 10;77(4):306-11.

26- Atiomo WU, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertility and sterility. 2003 Jul 1;80(1):143-5.

27- Zhang SW, Zhou J, Gober HJ, Leung WT, Wang L. Effect and mechanism of berberine against polycystic ovary syndrome. Biomedicine & Pharmacotherapy. 2021 Jun 1; 138:111468.

28- Mumusoglu S, Yildiz BO. Polycystic ovary syndrome phenotypes and prevalence: differential impact of diagnostic criteria and clinical versus unselected population. Current Opinion in Endocrine and Metabolic Research. 2020 Jun 1; 12:66-71.

29- Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Human reproduction. 2009 Sep 1;24(9):2286-92.

30- Pasquali R. Obesity and androgens: facts and perspectives. Fertility and sterility. 2006 May 1;85(5):1319-40.

31- Dumesic DA, Abbott DH, Sanchita S, Chazenbalk GD. Endocrine–metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective. Current opinion in endocrine and metabolic research. 2020 Jun 1; 12:41-8.

32- March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human reproduction. 2010 Feb 1;25(2):544-51.

33- Maleki V, Izadi A, Farsad-Naeimi A, Alizadeh M. Chromium supplementation does not improve weight loss or metabolic and hormonal variables in patients with polycystic ovary syndrome: A systematic review. Nutrition research. 2018 Aug 1; 56:1-0.

34- Fazelian S, Rouhani MH, Bank SS, Amani R. Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis. Journal of trace elements in medicine and biology. 2017 Jul 1; 42:92-6.

35- Rajaei S, Alihemmati A, Abedelahi A. Antioxidant effect of genistein on ovarian tissue morphology, oxidant and antioxidant activity in rats with induced polycystic ovary syndrome. International Journal of Reproductive BioMedicine. 2019 Jan;17(1):11.

36- Ibrahim YF, Alorabi M, Abdelzaher WY, Toni ND, Thabet K, Hegazy A, Bahaa HA, Batiha GE, Welson NN, Morsy MA, Venugopala KN. Diacerein ameliorates letrozole-induced polycystic ovarian syndrome in rats. Biomedicine & Pharmacotherapy. 2022 May 1; 149:112870.

37- Niswender GD, Juengel JL, Silva PJ, Rollyson MK, McIntush EW. Mechanisms controlling the function and life span of the corpus luteum. Physiol Rev. 2000;80(1):1–29.

38- Baravalle C, Salvetti NR, Mira GA, Pezzone N, Ortega HH. Microscopic characterization of follicular structures in letrozole-induced polycystic ovarian syndrome in the rat. Archives of medical research. 2006 Oct 1;37(7):830-9.